冠状动脉内注射替罗非班对老年心肌梗死患者介入治疗中无复流的疗效观察被引量：1

下载PDF

导出

摘要目前，直接PCI已经成为急性ST段抬高心肌梗死（STEMI）的优选治疗方法。然而，由于直接PCI术中“无复流现象”的大量出现，已成为PCI预后及心脏事件的独立危险因素。

作者张红雨王佩显曹艳君吴志国王立强仇宝华梅莲莲王淑静张霞

机构地区天津医科大学宝坻临床学院心内科天津医科大学总医院心内科

出处《中华老年心脑血管病杂志》 CAS 北大核心 2012年第4期431-432,共2页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

关键词无复流现象心肌梗死患者动脉内注射疗效观察介入治疗替罗非班急性ST段抬高心肌梗死直接PCI

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1Ndrepepa G,Tiroch K,Fusaro D. 5-yeay prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J].Journal of the American College of Cardiology,2010.2383-2389.
2Gibson CM,Cannon CP,Muphy SA. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs[J].Circulation,2000.125-130.
3Li DB,Hua Q,Liu Z. Predictor and long-term prognosis of angiographic slow/no reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction[J].Clinical Cardiology,2010.E7-E12.
4Van't hof AW,Valgimigli M. Defining the role of platelet glycopretein receptor inhibitors in STEMI:Focus on tirfiban[J].Drugs,2009.85-100.
5周鹏,颜红兵.血小板糖蛋白Ⅱb／Ⅲa受体抑制剂临床应用进展[J].中华心血管病杂志,2011,39(3):274-277. 被引量：6
6Friedland S,Eisenberg MJ,Shimony A. Meta-analysis of randomized controlled trials of intracornary versus intravenous administration of glycoprotein Ⅱb/Ⅲ a inhibitors during percutaneous coronary intervention for acute coronary syndrome[J].American Journal of Cardiology,2011.1244-1251.

二级参考文献28

1Niccoli G,Burzotta F,Galiuto L,et al.Myocardial no-reflow in humans.J Am Coll Cardiol,2009,54:281-292.
2De Luca G,Ucci G,Cassetti E,et al.Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:a meta-analysis.J Am Coll Cardiol,2009,53:1668-1673.
3Kushner FG,Hand M,Smith SC Jr,et al.2009 focused updates:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coil Cardiol,2009,54:2205-2241.
4Van't Hof AW,Ten Berg J,Heestermans T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2):a multicentre,double-blind,randomised controlled trial.Lancet,2008,372:537-546.
5Ercan E,Tengiz I,Duman C,et al.Effect of tirofiban on Creactive protein in non-ST-elevation myocardial infarction.Am Heart J,2004,147:E1.
6Nannizzi-Alaimo L,Alves VL,Phillips DR.Inhibitory effects of glycoprotein Ⅱ b/Ⅲ a antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.Circulation,2003,107:1123-1128.
7Heitzer T,Ollmann I,K(o)ke K,et al.Platelet glycoprotein Ⅱ b/Ⅲ a receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.Circulation,2003,108:536-541.
8The EPIC Investigation.Use of a monoclonal antibody directed against the platelet glycoprotein Ⅱ b/Ⅲ a receptor in high-risk coronary angioplasty.N Engl J Med,1994,330:956-961.
9EPISTENT Investigators.Randomised placebo-controlled and ballocn-angioplasty-controlled trial to assess safety of coronary steeting with use of platelet glycoprotein-Ⅱ b/Ⅲ a blockade.Lancet,1998,352:87-92.
10Kastrati A,Mehilli J,Neumann FJ,et al.Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment:the ISAR-REACT 2randomized trial.JAMA,2006,295:1531-1538.